摘要
目的探讨丹参多酚酸盐对冠心病患者冠状动脉介入术（PCI）和冠状动脉造影术后发生对比剂肾损害和对比剂肾病是否具有预防保护作用.方法将2011-02—2011-12住院行 PCI 和冠状动脉造影的120例患者随机分为实验组和对照组.实验组患者在围手术期使用丹参多酚酸盐,对照组静脉滴注等剂量0.9%氯化钠注射液.比较两组造影后48h 血肌酐（Scr）、肾小球滤过率（eGFR）、尿微量白蛋白（U-MA）、尿β2微球蛋白（β2-MG）的变化及对比剂肾病发生率,同时检测血浆 hs-CRP、IL-6、TNF-α、NO水平.结果实验组患者肾小球功能指标（Scr、eGFR）和 U-MA、β2-MG 均优于对照组.实验组患者发生对比剂肾病1例,对照组发生7例,实验组患者优于对照组.实验组患者血浆 hs-CRP、IL-6、TNF-α水平均低于对照组,而 NO 水平高于对照组.结论丹参多酚酸盐对对比剂肾损害和对比剂肾病的发生具有一定的预防作用,可能与其抗炎、增加舒血管物质作用有关.
Objective To investigate the protective effect of salvianolate on contrast-induced nephropathy （CIN） after coronary interventional therapy. Methods One hundred and twenty patients with coronary heart disease CHD, who underwent coronary intervention therapy were randomized into control group （n=64） and trial group （n=56）. Salvianolate injection was given to patients in trial group and equal volume of physiological saline injection was given to the control group perioperatively. Serum creatinine（Scr）, glomerular filtration rate （eGFR）, urine micro album （U-MA）, urinary β2 microglobulin （β2-MG） and plasma hsCRP, IL-6, TNF-α, NO were measured; incidence rate of CIN was documented 48h after coronary interventional therapy. Results Glomerular function index （Scr, eGFR） and renal tubular funtion （U-MA, β2-MG） of trial group were better than those of the control group. On case of CIN occurred in trial group and 7 in control group（P〈0.05）. There were significant differences plas-ma hsCRP, IL-6, TNF-α and NO levels between two groups. Plasma hsCRP, IL-6, TNF-α levels in trial group were lower and NO was higher than those in control group （P〈0.05）. Conclusion Salvianolate may protect patients undergoing coronory inter-vention therapy from contrast-induced nephropathy, which may be associated with its anti-inflammatory and vasodilatory effects.
出处
《浙江医学》
CAS
2012年第23期1883-1885,共3页
Zhejiang Medical Journal
关键词
丹参多酚酸盐
冠心病介入治疗
对比剂肾病
Salvianolate
Percutaneous transluminal coronary intervention
Contrast-induced nephropathy
